Gianotti N, Tambussi G, Boeri E, Lazzarin A
Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy.
J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):166-9.
Many patterns of mutations selected by HIV-1 protease inhibitors have been described, but in most cases isolates with these patterns have been obtained from pre-clinical studies or after failures of monotherapies. We compared genotype and phenotype in HIV-1 infected patients who have failed more than one PI-including regimen. Phenotypic resistance could arise also in the absence of specific primary mutations and in the presence of different substitutions among those known to confer resistance to ritonavir, indinavir or nelfinavir. The number of secondary mutations was significantly associated with phenotypic resistance for each protease inhibitor. Thus, more study of mutational patterns in heavily pretreated patients is warranted; in the mean time treatment choices might be optimized if phenotyping could integrate genotyping within this setting.
许多由HIV-1蛋白酶抑制剂选择的突变模式已被描述,但在大多数情况下,具有这些模式的分离株是从临床前研究或单一疗法失败后获得的。我们比较了接受过不止一种含蛋白酶抑制剂方案治疗但治疗失败的HIV-1感染患者的基因型和表型。在没有特定原发性突变以及存在已知对利托那韦、茚地那韦或奈非那韦耐药的不同替代突变的情况下,也可能出现表型耐药。每种蛋白酶抑制剂的二级突变数量与表型耐药显著相关。因此,有必要对接受过大量治疗的患者的突变模式进行更多研究;与此同时,如果在这种情况下表型分析能够整合基因分型,治疗选择可能会得到优化。